Daewon Pharmaceutical Co., Ltd.

KSE 003220.KS

Daewon Pharmaceutical Co., Ltd. Net Cash Used For Investing Activities for the year ending December 31, 2023: USD -53.72 M

Daewon Pharmaceutical Co., Ltd. Net Cash Used For Investing Activities is USD -53.72 M for the year ending December 31, 2023, a -145.59% change year over year. Net cash used for investing activities is total cash inflows and outflows related to activities intended to generate future income and cash flows from investments.
  • Daewon Pharmaceutical Co., Ltd. Net Cash Used For Investing Activities for the year ending December 31, 2022 was USD -21.87 M, a 37.20% change year over year.
  • Daewon Pharmaceutical Co., Ltd. Net Cash Used For Investing Activities for the year ending December 31, 2021 was USD -34.83 M, a -154.78% change year over year.
  • Daewon Pharmaceutical Co., Ltd. Net Cash Used For Investing Activities for the year ending December 31, 2020 was USD -13.67 M, a 66.74% change year over year.
  • Daewon Pharmaceutical Co., Ltd. Net Cash Used For Investing Activities for the year ending December 31, 2019 was USD -41.10 M, a -10.18% change year over year.
Key data
Date Net Cash Used For Investing Activities Net Cash Used Provided By Financing Activities Dividends Paid Capital Expenditure
Market news
Loading...
KSE: 003220.KS

Daewon Pharmaceutical Co., Ltd.

CEO Mr. Seung-Ryel Baek
IPO Date Sept. 29, 2005
Location South Korea
Headquarters 386 Cheonhodae-ro
Employees 1,260
Sector Health Care
Industries
Description

Daewon Pharmaceutical Co., Ltd., a pharmaceutical company, produces and sells medicine and medical supplies in South Korea. It offers various medicines for circulatory, respiratory, antibiotic, chemotherapy, and psychoneurosis uses. The company's principal products include Oramin-F Soft Cap, a multivitamin product; Pelubi Tablet, a NSAID product for pain relief; Freefol-MCT Inj., a microemulsion propofol for the anti-exogenous infectious bacteria; Megex-I Susp, a medicine that supplements subalimentation of cancer patients; Trigel Susp, a therapy for gastritis and duodenal ulcer; and Renamezin Cap, a spherical carbonaceous adsorbent for chronic kidney disease. It also exports its products to approximately 45 countries primarily in Asia, Central and South America, the Middle East, etc. The company was founded in 1958 and is headquartered in Seoul, South Korea.

Similar companies

003000.KS

Bukwang Pharmaceutical Co., Ltd.

USD 3.32

0.12%

001360.KS

SAMSUNG PHARM. Co., LTD.

USD 1.04

-1.27%

006280.KS

Green Cross Corporation

USD 108.37

-2.33%

019170.KS

Shin Poong Pharm.Co.,Ltd.

USD 7.51

2.04%

003850.KS

Boryung Corporation

USD 7.02

1.13%

StockViz Staff

January 15, 2025

Any question? Send us an email